USP8 is a novel target for overcoming gefitinib-resistance in lung cancer

PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. However, the vast majority of treated patients acquire resistance to EGFR-TKIs, due in large part to secondary...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Byun, Sanguine, Lee, Sung-Young, Jeong, Chul-Ho, Lee, Jihoon, Lim, Semi, Reddy, Kanamata, Farrand, Lee, Kim, Ji Young, Lee, Mee-Hyun, Lee, Ki Won, Bode, Ann M., Lee, Hyong Joo, Dong, Zigang
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3891300/
https://ncbi.nlm.nih.gov/pubmed/23748694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3696
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk